Candida parapsilosis Fungemia in a Patient With Spinal Cord Injury on Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Case Report
Abstract
Individuals with spinal cord injury (SCI) and neurogenic bladder often rely on catheterization programs, which increase the risk of urinary tract infections (UTIs). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), widely used in the management of diabetes mellitus (DM), chronic kidney disease (CKD), and congestive heart failure (CHF), promote urinary glucose excretion, potentially fostering an environment favorable to bacterial and fungal growth. This case describes a 53-year-old man with long-standing traumatic cervical SCI and a suprapubic catheter who presented with sepsis secondary to Candida parapsilosis fungemia, in the context of SGLT2i use for DM management. This report suggests that the combination of SGLT2i therapy and chronic catheterization may increase the risk of urinary tract and invasive fungal infections. While current evidence is lacking, further investigation is warranted, and clinicians should exercise caution when prescribing SGLT2i in patients with SCI and bladder catheter use.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.